Log in

Quest Diagnostics Stock Forecast, Price & News

-1.96 (-1.71 %)
(As of 09/17/2020 12:00 AM ET)
Today's Range
Now: $112.59
50-Day Range
MA: $117.25
52-Week Range
Now: $112.59
Volume914,048 shs
Average Volume1.61 million shs
Market Capitalization$15.12 billion
P/E Ratio20.43
Dividend Yield1.96%
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More
Quest Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 1.7Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.19 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services



Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$9.28 per share
Book Value$42.22 per share


Net Income$858 million


Market Cap$15.12 billion
Next Earnings Date10/27/2020 (Estimated)
-1.96 (-1.71 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

How has Quest Diagnostics' stock price been impacted by Coronavirus (COVID-19)?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DGX stock has increased by 12.9% and is now trading at $112.59.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Quest Diagnostics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Quest Diagnostics

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Quest Diagnostics

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) posted its quarterly earnings results on Thursday, July, 23rd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.01. The medical research company earned $1.83 billion during the quarter, compared to analysts' expectations of $1.81 billion. Quest Diagnostics had a return on equity of 13.78% and a net margin of 9.99%. Quest Diagnostics's revenue was down 6.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.73 EPS.
View Quest Diagnostics' earnings history

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Tuesday, August 18th. Investors of record on Tuesday, October 6th will be paid a dividend of $0.56 per share on Wednesday, October 21st. This represents a $2.24 annualized dividend and a dividend yield of 1.99%. The ex-dividend date is Monday, October 5th.
View Quest Diagnostics' dividend history

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY20 earnings guidance on Thursday, September, 10th. The company provided earnings per share (EPS) guidance of $7.50-9.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.03. The company issued revenue guidance of $8.4-8.8 billion, compared to the consensus revenue estimate of $8.55 billion.

What price target have analysts set for DGX?

17 brokers have issued twelve-month price objectives for Quest Diagnostics' shares. Their forecasts range from $99.00 to $151.00. On average, they expect Quest Diagnostics' stock price to reach $125.53 in the next year. This suggests a possible upside of 11.5% from the stock's current price.
View analysts' price targets for Quest Diagnostics

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a decline in short interest in August. As of August 14th, there was short interest totaling 2,760,000 shares, a decline of 13.5% from the July 30th total of 3,190,000 shares. Based on an average daily volume of 1,430,000 shares, the days-to-cover ratio is presently 1.9 days. Currently, 2.1% of the company's shares are sold short.
View Quest Diagnostics' Short Interest

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Micron Technology (MU), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Pfizer (PFE), NVIDIA (NVDA), Abbott Laboratories (ABT), Cisco Systems (CSCO) and Intel (INTC).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.36%), Davis Selected Advisers (2.88%), Victory Capital Management Inc. (1.99%), Nuveen Asset Management LLC (1.28%), Grantham Mayo Van Otterloo & Co. LLC (1.24%) and California Public Employees Retirement System (0.84%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski.
View institutional ownership trends for Quest Diagnostics

Which major investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., FIL Ltd, Marshall Wace North America L.P., Marshall Wace LLP, Vanguard Group Inc., PNC Financial Services Group Inc., State of Michigan Retirement System, and MUFG Securities EMEA plc. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Michael E Prevoznik, and Stephen H Rusckowski.
View insider buying and selling activity for Quest Diagnostics

Which major investors are buying Quest Diagnostics stock?

DGX stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Ceredex Value Advisors LLC, Nordea Investment Management AB, Sumitomo Mitsui Trust Holdings Inc., Balyasny Asset Management LLC, Skandinaviska Enskilda Banken AB publ, Grantham Mayo Van Otterloo & Co. LLC, and Canada Pension Plan Investment Board.
View insider buying and selling activity for Quest Diagnostics

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $112.59.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $15.12 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis. Quest Diagnostics employs 47,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]questdiagnostics.com.

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.